Eur J Pharmacol 553, 141-145, (2006). Brammer, M. K., Gilmore, D. L., & Matsumoto, R. R. View abstract in PubMed Post navigationPreviousPrevious post:Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.NextNext post:Sigma receptor type 1 gene expression variation in a group of Polish patients with Alzheimer’s disease and mild cognitive impairment.Related PostsAnavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
